We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nanowire Technology Developed to Detect Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 04 Jan 2018
Analyzing microRNAs (miRNAs) within urine extracellular vesicles (EVs) is important for realizing miRNA-based, simple, and noninvasive early disease diagnoses and timely medical checkups.

A new approach for detecting cancer biomarkers in urine has been developed using a device composed of nanowires anchored into a microfluidic substrate. More...
This device enables EV collections at high efficiency and in situ extractions of various miRNAs of different sequences (around 1,000 types) that significantly exceed the number of species being extracted by the conventional ultracentrifugation method.

Scientists at Nagoya University (Furo-cho, Japan) and their colleagues fabricated nanowire-anchored microfluidic device for in situ extraction of urine EV–encapsulated miRNAs was fabricated by bonding the nanowire-embedded polydimethylsiloxane (PDMS) substrate and a herringbone-structured PDMS substrate. This new approach relies on playing the forces of negatively charged EVs off of positively charged nanowires to extract the miRNAs from the urine of patients with a variety of diseases. The team looked at samples from patients with pancreatic, liver, bladder, and prostate cancer, in addition to healthy subjects.

The scientists used a syringe pump to flow urine into the device, and then transferred the extracted samples on Toray's 3D-Gene microarray platform (Tokyo, Japan) for miRNA analysis by pipetting. Using the device, they were able to detect 1,106 different types of miRNAs in a single milliliter, versus an average yield of 200 to 400 miRNAs in total obtained using conventional methods, such as centrifugation.

The mechanical stability of the anchored nanowires during the buffer flow, as well as to the electrostatic collection of EVs onto the nanowires attributed to the success of the device. The approach yielded potential cancer-related miRNAs in urine for not only urological malignancies such as prostate cancer and bladder cancer, but also non-urological ones such as liver cancer and pancreatic cancer, the scientists believe it will be widely applicable.

Takao Yasui, PhD. an assistant professor and corresponding author of the study, said, “Our developed device could allow us to collect thousands of urinary microRNAs from only 1 mL of urine. Our new approach should allow scientists to move closer to the long-term goal of urinary miRNA-based early diagnoses and timely medical checkups for a variety of cancers.” The study was published on December 15, 2017, in the journal Science Advances.

Related Links:
Nagoya University
Toray Industries


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.